Slide 1: Full-Year results 2025
Full-Year results 2025 René Willi, CEO Jennifer Dean, CFO February 26, 2026 Providing innovative solutions to help people live healthier and more confident lives
Slide 2: Disclaimer and important notes / Safe harbor statement
Disclaimer and important notes / Safe harbor statement under the US private securities litigation reform act 1995 This presentation contains forward-looking statements that are based on management’s current assumptions and expectations concerning future developments, including but not limited to, pr
Slide 3: Highlights and Business Review
Highlights and Business Review René Willi, CEO G System (and cannula): a versatile solution for biomaterial storage and delivery
Slide 4: Resilient performance with strong profit gains
Resilient performance with strong profit gains Highlights Group Revenues1 Adjusted EBITDA margin up 90 bps YoY Gross profit up 310 bps 448.0 m to 20.0% to 161.9m delivering a strong Gross profit -4.8% organic3 -7.4% reported2 Exceeded guidance range of margin of 36.1% in line with revised guidance 1
Slide 5: Business unit revenue and key drivers
Business unit revenue and key drivers Healthcare Segment Consumer & Industrial (C&I) Segment Drug Dental Surgery Industry Beauty Delivery 120.1 34.2 17.3 124.3 152.1 +5.9% -19.6% +0.4% +1.4% -12.9% • Higher share in faster • Increased dual sourcing • Flat year-on-year, • Growth despite sluggish • We
Slide 6: Financial Review
Financial Review Jennifer Dean, CFO A MIXPACTM Peeler cartridge for 2K adhesives, applied by a 1K MK H40PS dispenser
Slide 7: Significant improvement in margin and profitability
Significant improvement in margin and profitability CHF millions FY 2025 FY 2024 change • Group revenues declined YoY by 4.8% Revenue 448.0 483.9 -7.4% organically and by 7.4% on a reported basis, in Organic revenue growth – – -4.8% line with guidance Gross profit 161.9 159.7 +1.4% • Gross profit ma
Slide 8: Growth in Dental, Surgery & Industry offset by Drug Delivery & Beauty
Growth in Dental, Surgery & Industry offset by Drug Delivery & Beauty -7.4% -4.8% organic Business Units % 7 0 2 share of Revenue 484 (9) (23) 461 (13) 448 34% C&I 28% 4% 7% % Change in organic growth Healthcare 27% +5.9% +0.4% -19.6% +1.4% -12.9% Revenue Dental Drug Drug Delivery Industry Beauty Or
Slide 9: Strong gross profit margin in Healthcare and C&I
Strong gross profit margin in Healthcare and C&I Healthcare gross profit C&I gross profit 92.0 50.8% 51.8% 76.0 23.3% 26.9% margin margin margin margin 90.0 74.0 88.0 72.0 86.0 70.0 84.0 68.0 82.0 66.0 FY 24 FY 25 FY 24 FY 25 • Healthcare gross profit margin up +100 bps • C&I gross profit margin up
Slide 10: Profitability significantly above guidance range
Profitability significantly above guidance range Margin growth sequentially for four consecutive half- years Non-ops halved YoY 19.1% 7.7 20.0% 13.9 92.5 (12.7) 89.7 0.2 (11.9) Adj. EBITDA Volume Pricing Margin Operating Non-ops Adj. EBITDA FY 2024 and mix expenses & others FY 2025 Chart figures in
Slide 11: EBIT – Positively impacted by Gross profit margin growth and lower OPEX
EBIT – Positively impacted by Gross profit margin growth and lower OPEX 25.0 5.1% 20.0 • EBIT increased by CHF 9.9m to CHF 22.8m (+76.7% YoY) and EBIT as % of revenues was 15.0 2.7% 5.1% (+240 bps YoY) 10.0 • Higher Dental in mix and Industry & Beauty margin gains achieved through Growth & 5.0 Effic
Slide 12: Lower Operating Net Cash Flow due to non-repeat high NWC contribution in 2024
Lower Operating Net Cash Flow due to non-repeat high NWC contribution in 2024 9.9 0.7 (4.7) (2.0) 61.0 (3.2) 1.3 1.7 40.3 (24.3) ONCF EBIT Amortization Depreciation Impairments Addition to Net Working Other Net Others / FX ONCF FY 2024 Assets Capital Current Asset FY 2025 Chart figures in CHF millio
Slide 13: Strategy & Outlook
Strategy & Outlook Two-component 5mL cartridge with ColibriTM mixing tip
Slide 14: Strategic Priorities To Ensure Sustainable Growth
Strategic Priorities To Ensure Sustainable Growth 1 Transform medmix into a high-performance organization Healthcare Segment: Dental – Portfolio optimization 6 2 Create the next generation of dental applicators Healthcare Segment: Surgery – C&I segment – 5 3 Becoming a strategic partner Expand margi
Slide 15: Transform medmix into a high-performance organization
Transform medmix into a high-performance organization Cultural Transformation Driving High Performance New organizational model Performance Customer Agility & fast culture Centricity decision taking Accountability & ownership 15
Slide 16: Solid pipeline of Drug Delivery projects
Solid pipeline of Drug Delivery projects Drug Therapy Platform 2025 2026 2027 2028 2029 2030 Originator Diabetes (Emergency) PiccoJectTM Generic Andrology PiccoJectTM Biosimilar Growth Disorder Custom Bone Metabolism, Biosimilar D-FlexTM Rheumatology, Obesity Originator Rheumatoid Arthritis PiccoJec
Slide 17: Growth & Efficiency Program: positively impacting profitability
Growth & Efficiency Program: positively impacting profitability On track to deliver planned cost-out 33 3 30 CHF 4.3m 7.4 secured savings Efficiency gains and leaner organizational (out of CHF 7.4m) structure achieved through: 19.6 Operational Excellence: Upsides of • Automation projects 14.5m in ma
Slide 18: Capital Allocation Principles
Capital Allocation Principles Maintain strong balance sheet Innovation: Accelerate development of next generation applicators Invest in high-growth, high-margin healthcare niches Invest in automation and other operational efficiency projects Sustainable dividend policy based on EPS 18
Slide 19: Innovation
Innovation 19 Cigar Shape Family ready-to-go Mascara packaging with a twisted wire mascara brush applicator
Slide 20: Surgery: medmix G-System in award-winning product
Surgery: medmix G-System in award-winning product Making our fast-growing OEM successful • Our client is a fast-growing OEM with an award- winning product • The customer’s hemostatic gel has been recognized by TIME Magazine as one of the Best Inventions of 2025 • medmix is strategic partner producin
Slide 21: Industry: MIXPAC ecopaCC cartridge – sustainable and reliable solutions for aerospace
Industry: MIXPACTM ecopaCCTM cartridge – sustainable and reliable solutions for aerospace • Collapsible cartridge delivering highest reliability for applications in various segments like aerospace and others • Sustainable, waste-cutting and logistics- efficient • Full production ramp up in Jan-Feb 2
Slide 22: Dental: Enhanced customer centricity and customization
Dental: Enhanced customer centricity and customization FleXa • Modular Syringe platform for single- component dental materials that adapts to our customers brand and elevates every dental experience 22
Slide 23: Outlook
Outlook 2026 guidance • Flat to low single digit organic revenue growth • Adjusted EBITDA margin of around 20% Mid-term guidance (3 years) • Revenue CAGR above 4% (unchanged) • Adjusted EBITDA margin above 21% (from above 20%) PiccoJectTM: two-step activation autoinjector platform for subcutaneous d
Slide 24: Key Takeaways
Key Takeaways Good progress in strategic priorities to grow 01 Strategy profitably in attractive niche markets Strong profitability gains in Healthcare and C&I 02 Performance Topline growth in 2026, after transition year Performance culture through leaner and agile 03 Culture organization with clear
Slide 25: Q&A
Q&A René Willi, CEO Jennifer Dean, CFO
Slide 26: Your Investor Relations contact
Your Investor Relations contact Domenico Truncellito Head Corporate Communications & Investor Relations Phone: +41 41 723 73 57 E-mail: investorrelations@medmix.com medmix Group AG Neuhofstrasse 20 6340 Baar Switzerland